The Science

The
science behind regenerative products and light-based wellness

“Regenerative medicine” describes a broad field—not one product, one
mechanism, or one level of evidence. Structural tissue allografts,
stem-cell therapies, extracellular vesicles, peptide medicines,
compounded formulations, and photobiomodulation are scientifically and
regulatorily distinct. Understanding those differences is essential for
responsible evaluation.

BioCellara organizes the science into five clear categories and
directs providers to current product documentation, primary research,
and regulatory resources.

1. Structural
connective-tissue allografts

Connective tissue contains extracellular-matrix components such as
collagens, glycoproteins, proteoglycans, and elastin. Depending on its
source and processing, an allograft may be designed to provide a
structural matrix at a surgical site.

It is important not to describe every birth-tissue allograft as a
“stem-cell treatment.” A structural allograft’s identity and intended
use are determined by its composition, processing, labeling, and
applicable regulatory pathway. Product-specific claims should come from
current manufacturer documentation—not assumptions about the source
tissue.

Resources:

• CTM Biomedical
  product design and intended use
• CTM Biomedical
  product information
• Extracellular
  matrix as a biological scaffold material — PubMed
• 21
  CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based
  Products

2. Stem-cell science

Stem cells are defined by their capacity for self-renewal and their
ability to develop into one or more specialized cell types. Different
stem-cell types have different biological capabilities, sources,
research uses, and regulatory requirements.

The best-established routine stem-cell treatments are hematopoietic
stem-cell transplants used for certain blood, immune-system, and
cancer-related indications. Many other proposed stem-cell uses remain
investigational. A product’s origin from umbilical cord, placental,
adipose, or marrow tissue does not by itself establish that it is an
approved stem-cell therapy or that viable stem cells are present in the
finished product.

Resources:

• NIH Stem
  Cell Basics
• What
  Are Stem Cells? — National Institute of General Medical
  Sciences
• FDA
  Consumer Alert on Regenerative Medicine Products
• ISSCR:
  9 Things to Know About Stem Cell Treatments

3. Extracellular
vesicles and exosome research

Extracellular vesicles, including particles described as exosomes,
are being studied for their role in cell-to-cell communication. Research
may examine cargo such as proteins, lipids, or nucleic acids and how
these particles interact with cells in laboratory or preclinical
settings.

Research findings about extracellular-vesicle biology should not be
treated as proof that a specific commercial product produces a clinical
outcome. FDA states that there are currently no FDA-approved exosome
products. Product-specific status, intended use, and supporting
documentation must be evaluated independently.

Resources:

• FDA
  Public Safety Notification on Exosome Products
• FDA
  Consumer Alert on Regenerative Medicine Products
• Platinum Biologics
  research and product-status information

4. Peptide
science and compounded formulations

Peptides are short chains of amino acids. Some peptide medicines have
undergone FDA review and are approved for specific indications; other
peptides remain investigational, are sold for research, or may appear in
compounded formulations under limited circumstances.

These categories should never be presented as interchangeable.
Compounded drugs are not FDA-approved, and FDA does not verify their
safety, effectiveness, or quality before marketing. Providers should
evaluate the specific substance, patient need, pharmacy or
outsourcing-facility status, state law, prescribing requirements,
current FDA information, and available evidence.

Resources:

• Compounding
  and the FDA: Questions and Answers
• FDA:
  Certain Bulk Drug Substances May Present Significant Safety
  Risks
• Therapeutic
  peptides: historical perspectives and development trends —
  PubMed
• Therapeutic
  peptides: current applications and future directions — PMC

5.
Photobiomodulation and red-light research

Photobiomodulation is the study and use of non-ionizing visible-red
and near-infrared light at selected wavelengths and doses. Research has
examined how absorbed light may interact with cellular chromophores,
mitochondrial signaling, nitric oxide, reactive oxygen species, and
downstream biological pathways.

Results vary by wavelength, irradiance, total dose, pulse parameters,
exposure time, tissue depth, device, and study population. General
photobiomodulation research does not establish that every red-light
device produces the same result, and it should not be used to imply that
a general-wellness panel is authorized to diagnose or treat disease.

Resources:

• The
  Mechanisms and Efficacy of Photobiomodulation Therapy — PMC
• Photobiomodulation—Underlying
  Mechanism and Clinical Applications — PMC
• Photobiomodulation CME
  Part I: Overview and Mechanism — PubMed
• The Clinical
  Applications of Low-Level Light Therapy — PubMed

How BioCellara evaluates
information

• Start with current labeling, instructions for use, certificates, and
  manufacturer documentation.
• Separate in-vitro, animal, observational, and randomized human
  evidence.
• Confirm whether a publication studied the same product, formulation,
  route, dose, device, and intended use.
• Review FDA approval, clearance, registration, HCT/P status,
  compounding status, and state requirements as separate concepts.
• Avoid translating a biological mechanism into a guaranteed patient
  outcome.

Explore the full research library

Disclaimer: This page is educational and does not provide medical,
legal, or regulatory advice. Clinical and purchasing decisions should be
based on current product documentation, applicable law, and independent
professional judgment.